2 completed, 2 terminated. 4 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Completed 2, Terminated 2 |
Follow BioNTech US Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Study of the Safety and Activity of the Investigational Cell Therapy NEO-PTC-01 in Patients With Advanced Melanoma NEO-PTC-01, IL-2, PD-1 Inhibitors - Unresectable Melanoma, Metastatic Melanoma | Phase 1 | Terminated | BioNTech US Inc. | 22 | 2020-12-01 | 2025-04-06 |
| A Personal Cancer Vaccine (NEO-PV-01) and APX005M or Ipilimumab With Nivolumab in Patients With Advanced Melanoma NEO-PV-01, Nivolumab, Adjuvant - Metastatic Melanoma | Phase 1 | Terminated | BioNTech US Inc. | 22 | 2018-10-08 | 2020-09-03 |
| A Personal Cancer Vaccine (NEO-PV-01) With Pembrolizumab and Chemotherapy for Patients With Lung Cancer NEO-PV-01, Pembrolizumab, Adjuvant - Carcinoma, Non-Small-Cell Lung, Lung Cancer | Phase 1 | Completed | BioNTech US Inc. | 38 | 2018-05-04 | 2021-02-26 |
| A Personal Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer NEO-PV-01, Nivolumab, Adjuvant - Urinary Bladder Cancer, Bladder Tumors | Phase 1 | Completed | BioNTech US Inc. | 34 | 2016-10-01 | 2021-02-25 |
Melanoma (3) · Carcinoma, Non-Small-Cell Lung (2) · Lung Neoplasms (2) · Skin Neoplasms (1) · Urinary Bladder Neoplasms (1)
Adjuvants, Pharmaceutic (3) · poly ICLC (3) · Nivolumab (2) · Carboplatin (1) · Immune Checkpoint Inhibitors (1) · Interleukin-2 (1) · Ipilimumab (1) · Pemetrexed (1) · pembrolizumab (1) · sotigalimab (1)
United States (3) · Belgium (1) · Netherlands (1)
Mark DeMario, MD (3)
PMID 33064988, PMID 33294862, PMID 39753970
2019 (1), 2023 (1)